Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Vaccinex (VCNX) has issued an update.
Vaccinex, Inc. has announced the completion of the final patient visit in its SIGNAL-AD Phase 1b/2 study, evaluating pepinemab as a treatment for Alzheimer’s disease. This milestone marks a significant step forward in the development of the drug, capturing the interest of investors and stakeholders in the potential impact on Alzheimer’s treatment and Vaccinex’s future prospects.
For a thorough assessment of VCNX stock, go to TipRanks’ Stock Analysis page.